Literature DB >> 20886540

miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes.

Xu-Bao Shi1, Lingru Xue, Ai-Hong Ma, Clifford G Tepper, Hsing-Jien Kung, Ralph W deVere White.   

Abstract

BACKGROUND: Increasing evidence demonstrates that aberrantly regulated microRNAs (miRNAs) contribute to the initiation and progression of human cancer. We previously have demonstrated that miR-125b stimulated the growth of prostate cancer (CaP) cells. In this study, we further determined the influence of miR-125b on the pathogenesis of CaP.
METHODS: To evaluate the effect of miR-125b on xenograft tumor growth, male athymic mice were subcutaneously injected with PC-346C-miR-125b cells that stably overexpressed miR-125b. Potential direct target transcripts of miR-125b were identified using a bioinformatics approach and three miR-125b targeted molecules were confirmed by means of biochemical analyses.
RESULTS: Enforced expression of miR-125b promoted tumor growth in both intact and castrated male nude mice. In an effort to define the molecular mechanism(s) mediating its tumor growth properties, we found that miR-125b directly targets eight transcripts, including three key pro-apoptotic genes: p53, Puma, and Bak1. Increasing the abundance of miR-125b resulted in a dramatic decrease in the levels of these three proteins in CaP cells. A direct repressive effect on each of these was supported by the ability of miR-125b to significantly reduce the activity of luciferase reporters containing their 3'-untranslated regions of each gene encompassing the miR-125b-binding sites. Additionally, we found that repression of miR-125b activity was able to sensitize CaP cells to different therapeutic interventions.
CONCLUSION: Data obtained in this study demonstrate that miR-125b promotes growth of prostatic xenograft tumors by down-regulating three key pro-apoptotic genes. This suggests that miR-125b is oncogenic and makes it an attractive therapeutic target in CaP.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20886540      PMCID: PMC3017658          DOI: 10.1002/pros.21270

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  49 in total

1.  Insertion of microRNA-125b-1, a human homologue of lin-4, into a rearranged immunoglobulin heavy chain gene locus in a patient with precursor B-cell acute lymphoblastic leukemia.

Authors:  T Sonoki; E Iwanaga; H Mitsuya; N Asou
Journal:  Leukemia       Date:  2005-11       Impact factor: 11.528

2.  Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.

Authors:  Benjamin P Lewis; Christopher B Burge; David P Bartel
Journal:  Cell       Date:  2005-01-14       Impact factor: 41.582

3.  Depletion of human micro-RNA miR-125b reveals that it is critical for the proliferation of differentiated cells but not for the down-regulation of putative targets during differentiation.

Authors:  Yong Sun Lee; Hak Kyun Kim; Sangmi Chung; Kwang-Soo Kim; Anindya Dutta
Journal:  J Biol Chem       Date:  2005-02-18       Impact factor: 5.157

4.  RAKE and LNA-ISH reveal microRNA expression and localization in archival human brain.

Authors:  Peter T Nelson; Don A Baldwin; Wigard P Kloosterman; Sakari Kauppinen; Ronald H A Plasterk; Zissimos Mourelatos
Journal:  RNA       Date:  2005-12-22       Impact factor: 4.942

5.  Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis.

Authors:  Tetsuya Ueda; Stefano Volinia; Hiroshi Okumura; Masayoshi Shimizu; Cristian Taccioli; Simona Rossi; Hansjuerg Alder; Chang-gong Liu; Naohide Oue; Wataru Yasui; Kazuhiro Yoshida; Hiroki Sasaki; Sachiyo Nomura; Yasuyuki Seto; Michio Kaminishi; George A Calin; Carlo M Croce
Journal:  Lancet Oncol       Date:  2009-12-18       Impact factor: 41.316

6.  Androgen receptor modifications in prostate cancer cells upon long-termandrogen ablation and antiandrogen treatment.

Authors:  Rute B Marques; Sigrun Erkens-Schulze; Corrina M de Ridder; Karin G Hermans; Kati Waltering; Tapio Visakorpi; Jan Trapman; Johannes C Romijn; Wytske M van Weerden; Guido Jenster
Journal:  Int J Cancer       Date:  2005-11-01       Impact factor: 7.396

7.  Bax and Bak are required for apoptosis induction by sulforaphane, a cruciferous vegetable-derived cancer chemopreventive agent.

Authors:  Sunga Choi; Shivendra V Singh
Journal:  Cancer Res       Date:  2005-03-01       Impact factor: 12.701

8.  Molecular alterations associated with LNCaP cell progression to androgen independence.

Authors:  Xu-Bao Shi; Ai-Hong Ma; Clifford G Tepper; Liang Xia; Jeffrey P Gregg; Regina Gandour-Edwards; Philip C Mack; Hsing-Jien Kung; Ralph W deVere White
Journal:  Prostate       Date:  2004-08-01       Impact factor: 4.104

9.  The human myotubularin-related protein suppresses the growth of lung carcinoma cells.

Authors:  Young Do Yoo; Sun Mi Cho; Jun Suk Kim; Yoon Soo Chang; Chul Min Ahn; Hyung Jung Kim
Journal:  Oncol Rep       Date:  2004-09       Impact factor: 3.906

10.  A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value.

Authors:  Xu-Bao Shi; Regina Gandour-Edwards; Laurel A Beckett; Arline D Deitch; Ralph W de Vere White
Journal:  BJU Int       Date:  2004-11       Impact factor: 5.588

View more
  84 in total

1.  CFTR mediates bicarbonate-dependent activation of miR-125b in preimplantation embryo development.

Authors:  Yong Chao Lu; Hui Chen; Kin Lam Fok; Lai Ling Tsang; Mei Kuen Yu; Xiao Hu Zhang; Jing Chen; Xiaohua Jiang; Yiu Wa Chung; Alvin Chun Hang Ma; Anskar Yu Hung Leung; He Feng Huang; Hsiao Chang Chan
Journal:  Cell Res       Date:  2012-06-05       Impact factor: 25.617

Review 2.  Shielding the messenger (RNA): microRNA-based anticancer therapies.

Authors:  Elena Sotillo; Andrei Thomas-Tikhonenko
Journal:  Pharmacol Ther       Date:  2011-04-14       Impact factor: 12.310

Review 3.  The roles of microRNAs in the progression of castration-resistant prostate cancer.

Authors:  Satoko Kojima; Yusuke Goto; Yukio Naya
Journal:  J Hum Genet       Date:  2016-06-09       Impact factor: 3.172

Review 4.  Vitamin D receptor and RXR in the post-genomic era.

Authors:  Mark D Long; Lara E Sucheston-Campbell; Moray J Campbell
Journal:  J Cell Physiol       Date:  2015-04       Impact factor: 6.384

Review 5.  MicroRNAs in prostate cancer: From function to biomarker discovery.

Authors:  Ahmed A Moustafa; Hogyoung Kim; Rasha S Albeltagy; Ola H El-Habit; Asim B Abdel-Mageed
Journal:  Exp Biol Med (Maywood)       Date:  2018-06

6.  MicroRNA-125b in peripheral blood: a potential biomarker for severity and prognosis of children with viral encephalitis.

Authors:  Qin-Ling Gao; Yun-Xia Ma; Da-Wei Yuan; Qing-Cai Zhang; Jun Zeng; Hao Li
Journal:  Neurol Sci       Date:  2017-05-13       Impact factor: 3.307

7.  miR-125b functions as a key mediator for snail-induced stem cell propagation and chemoresistance.

Authors:  Zixing Liu; Hao Liu; Shruti Desai; David C Schmitt; Ming Zhou; Hung T Khong; Kristine S Klos; Steven McClellan; Oystein Fodstad; Ming Tan
Journal:  J Biol Chem       Date:  2012-12-19       Impact factor: 5.157

Review 8.  The role of microRNA in castration-resistant prostate cancer.

Authors:  William Thieu; Derya Tilki; Ralph de Vere White; Christopher P Evans
Journal:  Urol Oncol       Date:  2014-07       Impact factor: 3.498

9.  Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells.

Authors:  X-B Shi; L Xue; A-H Ma; C G Tepper; R Gandour-Edwards; H-J Kung; R W deVere White
Journal:  Oncogene       Date:  2012-10-15       Impact factor: 9.867

10.  miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and Src.

Authors:  Xu-Bao Shi; Ai-Hong Ma; Lingru Xue; Meimei Li; Hao G Nguyen; Joy C Yang; Clifford G Tepper; Regina Gandour-Edwards; Christopher P Evans; Hsing-Jien Kung; Ralph W deVere White
Journal:  Cancer Res       Date:  2015-11-16       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.